Nekton Capital Ltd. Takes $449,000 Position in Enfusion, Inc. (NYSE:ENFN)

Nekton Capital Ltd. acquired a new position in Enfusion, Inc. (NYSE:ENFN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 43,611 shares of the company’s stock, valued at approximately $449,000. Enfusion accounts for approximately 1.2% of Nekton Capital Ltd.’s investment portfolio, making the stock its 7th largest position.

Several other large investors have also made changes to their positions in ENFN. Tower Research Capital LLC TRC increased its position in Enfusion by 58.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock worth $136,000 after buying an additional 4,889 shares during the period. MetLife Investment Management LLC grew its stake in shares of Enfusion by 17.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,785 shares of the company’s stock worth $348,000 after acquiring an additional 4,993 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Enfusion by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 798,870 shares of the company’s stock worth $8,229,000 after acquiring an additional 110,364 shares during the period. Marshall Wace LLP acquired a new position in Enfusion during the 4th quarter valued at $1,142,000. Finally, Walleye Capital LLC bought a new stake in Enfusion in the 4th quarter valued at $341,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Insider Buying and Selling

In other news, COO Neal Pawar sold 2,769 shares of Enfusion stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the transaction, the chief operating officer now owns 1,231,627 shares in the company, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Oleg Movchan sold 2,790 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the sale, the chief executive officer now owns 643,299 shares in the company, valued at approximately $7,385,072.52. This trade represents a 0.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,223 shares of company stock worth $754,778 in the last 90 days. 36.44% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Piper Sandler upped their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd.

Enfusion Stock Performance

NYSE:ENFN opened at $10.85 on Tuesday. The company has a 50-day moving average of $11.07 and a 200-day moving average of $10.44. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. Sell-side analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.